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Key messages
What is already known about this subject?
 ► abatacept in combination with methotrexate induc-
es remission more often than methotrexate alone 
after 12 months of treatment, with a greater propor-
tion of patients with rheumatoid arthritis (ra) main-
taining remission over 6 months following treatment 
withdrawal.
What does this study add?
 ► these final results of the assessing Very early 
rheumatoid arthritis treatment (aVert) study 
demonstrate that, after receiving only 12 months 
of disease-modifying antirheumatic drug therapy 
before withdrawal of all ra treatments, the majority 
of patients will experience a flare within 6 months 
of treatment withdrawal and very few will sustain 
major responses for 1 year.
 ► the study provides the most complete data on 
re-treatment with abatacept plus methotrexate 
showing that this combination can restore remission 
or low disease activity in many patients who experi-
enced a flare after treatment withdrawal, with good 
tolerability.
How might this impact on clinical practice?
 ► this is the first study to examine the effects of com-
plete and rapid removal of all ra therapy, creating 
data that will inform future efforts to develop off-
drug remission strategies.
AbstrAct
Objectives to complete reporting of outcomes after total 
withdrawal of all rheumatoid arthritis (ra) therapy and re-
treatment after flare in assessing Very early rheumatoid 
arthritis treatment study (nct01142726).
Methods Patients with early ra were initially randomised 
to double-blind, weekly subcutaneous abatacept plus 
methotrexate, or abatacept or methotrexate monotherapy. 
at month 12, patients with Disease activity Score (DaS)28 
c reactive protein (crP) <3.2 had all ra treatments rapidly 
withdrawn and were observed for ≤12 months or until 
flare. after ≥3 months’ withdrawal, patients with protocol-
defined ra flare received open-label abatacept plus 
methotrexate for 6 months (re-treatment).
Results  Proportion of patients in DaS28-crP–defined 
remission remained numerically higher in original 
abatacept plus methotrexate and abatacept arms versus 
methotrexate arm up to day 253 of withdrawal. at the 
end of the withdrawal period, few patients remained in 
remission across all arms: 9/73 (12.3%), 7/50 (14.0%) 
and 6/53 (11.3%), respectively. For patients entering re-
treatment, after 6 months’ re-treatment, 95/124 (76.6%) 
and 78/124 (62.9%) patients achieved DaS28-crP 
<3.2 and <2.6, respectively; mean changes in DaS28-crP 
and Health assessment Questionnaire–Disability index 
scores from re-treatment baseline were –2.87 and 0.76, 
respectively. re-treatment was well tolerated; exposure-
adjusted infection rates per 100 patient-years were lower 
with abatacept plus methotrexate during withdrawal (7.2) 
and re-treatment (17.2) versus initial treatment periods of 
months 0–6 (116.6) and 6–12 (64.6).
Conclusions Most patients flared within 6 months of 
therapy withdrawal and few sustained major responses for 
1 year. re-treatment with abatacept plus methotrexate was 
effective and well tolerated in this controlled setting.
InTROduCTIOn
In early rheumatoid arthritis (RA), a window 
may exist during which intensive treatment 
can alter the disease course, leading to 
improved long-term outcomes.1 2 For patients 
achieving remission within this window, 
tapering or withdrawal of treatment may offer 
certain advantages if remission is sustained.3–5 
In order to develop biologic-free or even 
drug-free remission strategies,3 we must 
better understand the ability of current ther-
apies to sustain long-term off-drug remission, 
including the management of disease flares.
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Figure 1 Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP, Disease Activity Score 28-C 
reactive protein; D/C, discontinuation; MTX, methotrexate; RA, rheumatoid arthritis. Reprinted from Emery P, et al. Ann Rheum 
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by-nc/4.0/legalcode).
In the Assessing Very Early Rheumatoid arthritis Treat-
ment (AVERT) study, treatment-naïve patients with early 
RA were randomised to either subcutaneous abatacept 
plus methotrexate, subcutaneous abatacept or meth-
otrexate monotherapy for 1 year followed by complete 
withdrawal of all RA-specific therapeutic agents, including 
corticosteroids, and then monitored for flares before 
re-treating with abatacept plus methotrexate. As previ-
ously reported, it demonstrated the benefits, including 
MRI improvements, of abatacept plus methotrexate versus 
methotrexate alone in inducing remission at 12 months 
and maintaining remission over the first 6 months after 
withdrawal of all RA treatment.6 7 This report completes 
the description of the efficacy and safety outcomes over 
the full 12-month treatment withdrawal period and the 
benefits of 6 months of re-treatment after an RA flare. 
It also explores which clinical characteristics were asso-
ciated with flare or with regaining disease control after 
re-treatment.
MeTHOds
study design and patient population
Methodology of the phase IIIb AVERT study 
(NCT01142726) was published previously (figure 1).6 
In the initial 12-month, double-blind treatment period, 
patients were randomised (1:1:1) to subcutaneous abata-
cept plus oral methotrexate, abatacept monotherapy plus 
oral placebo, or methotrexate monotherapy plus subcu-
taneous placebo. After 12 months, patients with Disease 
Activity Score (DAS)28 C reactive protein (CRP) <3.2 
could enter a 12-month withdrawal period and all RA 
treatments were stopped—abatacept immediately, and 
methotrexate and corticosteroids tapered over 1 month. 
Patients with protocol-defined RA flare after month 15 
could receive open-label subcutaneous abatacept plus 
methotrexate in a 6-month re-treatment period. RA flare 
was defined as ≥2 of the following after the first 3 months 
of the withdrawal period: doubling of tender and swollen 
joint counts, increase in DAS28-CRP ≥1.2 (both from 
month 12) or investigator’s judgement of RA flare. Abata-
cept was administered at 125 mg/week and methotrexate 
titrated to 10–20 mg/week.
Eligibility criteria included age ≥18 years, active clinical 
synovitis of ≥2 joints for ≥8 weeks, persistent RA symptoms 
for ≤2 years, DAS28-CRP ≥3.2, anticyclic citrullinated 
peptide 2 (anti-CCP2) antibody positivity and metho-
trexate naïve/minimum exposure. Patients receiving 
oral corticosteroids had to be on a stable dose (≤10 mg/
day) at baseline and maintain that dose until month 12; 
randomisation was stratiﬁed by baseline corticosteroid 
use (yes/no).
Assessments and statistical analyses
Proportions of patients in the withdrawal period with 
remission, defined as DAS28-CRP <2.6, Clinical Disease 
Activity Index (CDAI) ≤2.8, Simplified Disease Activity 
Index (SDAI) ≤3.3 and Boolean criteria,8 and with low 
disease activity (LDA) defined as DAS28-CRP <3.2, were 
described over time. For patients entering withdrawal, 
time to first RA flare during withdrawal and predictors 
of time to flare were analysed using a Cox proportion-
al-hazards model including the following parameters at 
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initial study entry: randomised treatment, DAS28-CRP, 
swollen joint count, Patient Global Assessment of Disease 
Activity (PtGA), corticosteroid use, RA symptom dura-
tion, smoking status and anti-CCP2 antibody status.
Summary statistics were generated for the mean change 
from re-treatment baseline to the end of re-treatment in 
DAS28-CRP and Health Assessment Questionnaire-Dis-
ability Index (HAQ-DI) scores, and for proportions of 
patients with DAS28-CRP remission and LDA at the end 
of re-treatment. Re-treatment baseline was the last assess-
ment within 30 days before the first re-treatment dose. 
DAS28-CRP was also summarised by original treatment 
group, where baseline was the day of starting re-treat-
ment. The 95% CIs for mean change was based on a 
t-test. Achievement of DAS28-CRP remission at the end 
of re-treatment was tested using an adjusted logistic 
regression model, including the same parameters used 
for the Cox proportional-hazards model.
Deaths, serious adverse events (SAEs) and serious infec-
tions were summarised over the withdrawal and re-treat-
ment periods. Overall infection rates were compared 
over all study periods.
ResulTs
Patient disposition and baseline characteristics
Of 351 randomised patients, 290 (82.6%) completed 
the treatment period and 225 (64.1%) entered the with-
drawal period after achieving LDA, with 176/225 (78.2%) 
being in remission. Of the 225 patients, 172 (76.4%) 
discontinued the withdrawal phase due to RA flare, of 
whom 146/172 (84.9%) entered and 140/146 (95.9%) 
completed the re-treatment period. Six months after the 
initiation of the withdrawal period (month 18), 17/115 
(14.8%), 14/113 (12.4%) and 9/115 (7.8%) patients in 
the abatacept plus methotrexate, abatacept and metho-
trexate arms, respectively, had a sustained remission.
For patients who entered the withdrawal and re-treat-
ment periods, baseline characteristics (table 1) were 
similar to those of the original randomised population.6
efficacy: withdrawal period
Proportions of patients maintaining DAS28-CRP–defined 
drug-free remission remained numerically higher in 
the original abatacept plus methotrexate and abatacept 
arms versus methotrexate arm to day 253 of withdrawal 
(month 21: 15/73 (20.5%), 11/50 (22.0%) and 11/53 
(20.8%), respectively). At the end of the withdrawal 
period (month 24), the number of patients still in remis-
sion was very low and similar across the treatment arms: 
9/73 (12.3%) with abatacept plus methotrexate, 7/50 
(14.0%) with abatacept and 6/53 (11.3%) with meth-
otrexate (online supplementary figure S1). The same 
results were seen when using alternative definitions of 
disease remission: CDAI, SDAI and Boolean remission, 
and LDA (online supplementary table S1).
Patients who experienced a flare during the withdrawal 
period and subsequently entered the re-treatment period 
(n=146) were studied to determine if any characteristic 
at study entry could predict an earlier flare after treat-
ment withdrawal. Kaplan-Meier curves for time to proto-
col-defined first flare during withdrawal showed no clear 
differences between randomisation arms (figure 2). Cox 
proportional-hazards model of time to first flare after 
treatment withdrawal using various baseline parameters 
identified that only corticosteroid use at baseline was 
associated with a faster time to flare (p=0.0159; table 2).
efficacy: re-treatment period
As noted, only patients who experienced a flare between 
month 3 and month 12 of the withdrawal period entered 
the re-treatment period; a high proportion of these 
patients entered the re-treatment period and had eval-
uable efficacy data. Overall, 120 and 106 patients had 
DAS28-CRP and HAQ-DI assessments, respectively, 
within 30 days before the first re-treatment dose and after 
6 months of re-treatment.
During re-treatment, mean (SD) DAS28-CRP decreased 
from 5.28 (1.37) to 2.41 (0.94); mean change (95% CI) 
−2.87 (−3.13 to –2.60). There were no notable differences 
in mean improvement in DAS28-CRP by initial treatment 
arm (online supplementary table S2). After 6 months’ 
re-treatment, most evaluable patients (76.6%; 95/124) 
had reached LDA (DAS28-CRP <3.2), with 62.9% 
(78/124) achieving remission (DAS28-CRP<2.6). Mean 
(SD) HAQ-DI scores decreased during re-treatment: 1.40 
(0.63) versus 0.64 (0.57); mean change (95% CI) −0.76 
(−0.88 to –0.64).
Using an adjusted logistic regression model with the 
same baseline characteristics used to identify factors that 
could predict faster time to flare, only PtGA at study 
entry was associated with subsequent achievement of 
DAS28-CRP remission after re-treatment (p=0.0199; 
table 3).
safety
Two deaths were reported during the study, both in the 
methotrexate arm during withdrawal (due to respiratory 
failure and uterine neoplasm/renal failure). Neither 
was considered by the investigators to be related to study 
treatment.
During withdrawal, 7/225 patients had an SAE; two in 
the abatacept plus methotrexate arm (prostate cancer 
and postprocedural complication) and five in the meth-
otrexate arm (foot deformity, sciatica, respiratory failure, 
uterine neoplasm and renal failure, and pyelonephritis 
and urinary tract infection (all n=1)). None were consid-
ered to be related to study treatment. During re-treat-
ment, 4/146 patients had an SAE (tendon rupture, 
cholangitis, anaemia and abatacept overdose). Only 
abatacept overdose was considered related to the study 
drug.
Infection rates were low during the withdrawal and 
re-treatment periods, particularly when compared with 
the initial treatment period (table 4). No marked differ-
ences were seen between original treatment groups in 
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Figure 2 Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the 
re-treatment period (n=146). Patients who experienced a flare during the withdrawal period and subsequently entered the re-
treatment period were included in this analysis. Kaplan-Meier curves for time to protocol-defined first flare during withdrawal 
are shown. The Cox proportional-hazards model included the following baseline parameters: randomised treatment, DAS28-
CRP, swollen joint count, Patient Global Assessment of Disease Activity, corticosteroid use, RA symptom duration, smoking 
status and anticyclic citrullinated peptide 2 antibody status. RA flare was defined as ≥2 of doubling of tender and swollen joint 
counts from month 12, increase in DAS28-CRP ≥1.2 from month 12 or investigator’s clinical judgement of RA. DAS28-CRP, 
Disease Activity Score 28-C reactive protein; MTX, methotrexate; RA, rheumatoid arthritis.
the rate or type of infections. One serious infection was 
reported during treatment withdrawal (pyelonephritis 
in the methotrexate arm; 337.4 patient-years) and none 
during re-treatment (292.2 patient-years).
dIsCussIOn
AVERT investigated the feasibility of drug withdrawal in 
early RA, and employed the rapid withdrawal of all RA 
therapies and a strict definition of disease flare. This 
approach is not recommended in clinical practice. To our 
knowledge, this is the only controlled study in which the 
efficacy and safety of re-treatment have been examined. 
This unique analysis showed that re-treatment with abat-
acept plus methotrexate in patients experiencing disease 
flare after treatment withdrawal could restore remission 
or LDA in many patients.
During the 12 months following treatment withdrawal, 
most patients could not remain in drug-free remis-
sion, with many experiencing a flare within 6 months. 
Benefits of abatacept plus methotrexate versus metho-
trexate alone at 6 months after treatment withdrawal6 
did not persist over the second 6 months off treatment. 
Population selection criteria for severe disease used 
in this study—early, active disease and poor prognostic 
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Table 2 Cox proportional-hazards model of time to RA 
flare after study medication withdrawal*
Baseline parameter HR (95% CI) P value
Treatment
  Abatacept+MTX vs MTX 0.71 (0.46 to 1.09) 0.1171
  Abatacept vs MTX 0.80 (0.51 to 1.25) 0.3276
DAS28-CRP 0.84 (0.64 to 1.11) 0.2231
SJC (28 joints) 1.02 (1.00 to 1.04) 0.1060
PtGA (0–100 mm VAS) 1.00 (0.99 to 1.01) 0.9692
Baseline corticosteroid 
use (yes vs no)
1.71 (1.11 to 2.63) 0.0159
RA symptom duration (<3 
vs ≥3 months)
0.97 (0.66 to 1.42) 0.8588
Smoking status (yes† vs 
no)
0.91 (0.63 to 1.33) 0.6376
Anti-CCP2 (positive vs 
negative)
1.06 (0.73 to 1.54) 0.7543
HRs and p values were based on a Cox proportional-hazards 
model including the following baseline parameters: randomised 
treatment, DAS28-CRP, SJC, PtGA, corticosteroid use, RA 
symptom duration, smoking status and anti-CCP2 antibody 
status. RA flare was defined as ≥2 of doubling of tender and 
swollen joint counts from month 12, increase in DAS28-CRP ≥1.2 
from month 12 or investigator’s clinical judgement of RA.
*All randomised and treated patients who entered the withdrawal 
period (n=146).
†Includes previous and current smokers.
Anti-CCP2, anticyclic citrullinated peptide 2; DAS28-CRP, Disease 
Activity Score 28-C reactive protein ; MTX, methotrexate; PtGA, 
Patient Global Assessment of Disease Activity; RA, rheumatoid 
arthritis; SJC, swollen joint count; VAS, Visual Analogue Scale.
Table 3 Predictive factors for the achievement of DAS28-
CRP remission at the end of the re-treatment period*
Baseline parameter OR (95% CI) P value
Treatment
  Abatacept†+MTX vs 
MTX
1.71 (0.63 to 4.63) 0.6923
  Abatacept vs MTX 2.07 (0.74 to 5.77) 0.3026
DAS28-CRP 0.80 (0.44 to 1.47) 0.4727
SJC (28 joints) 1.00 (0.96 to 1.05) 0.9271
PtGA (0–100 mm VAS) 0.97 (0.94 to 1.00)† 0.0199
Baseline corticosteroid use 
(yes vs no)
1.34 (0.55 to 3.28) 0.5219
RA symptom duration (<3 
vs ≥3 months)
1.08 (0.44 to 2.66) 0.8634
Smoking status (yes‡ vs 
no)
1.16 (0.49 to 2.79) 0.7346
Anti-CCP2 (positive vs 
negative)§
1.62 (0.69 to 3.80) 0.2730
ORs and p values were based on an adjusted logistic regression 
model including the following baseline parameters: randomised 
treatment, DAS28-CRP, SJC, PtGA, corticosteroid use, RA 
symptom duration, smoking status and anti-CCP2 antibody 
status.
*All randomised and treated patients who entered the withdrawal 
period.
†Due to rounding, the upper 95% CI value of 0.995 is shown as 
1.00.
‡Includes previous and current smokers.
§At the end of the treatment period, respectively, 8/98 
(8%), 1/85 (1%) and 1/94 (1%) of patients treated with 
abatacept+methotrexate, abatacept and methotrexate became 
anti-CCP2 seronegative.
Anti-CCP2, anticyclic citrullinated peptide 2; DAS28-CRP, Disease 
Activity Score 28-C reactive protein; MTX, methotrexate; PtGA, 
Patient Global Assessment of Disease Activity; RA, rheumatoid 
arthritis; SJC, swollen joint count; VAS, Visual Analogue Scale.
indicators (anticitrullinated peptide antibody (ACPA) 
positive)6—were inadequate to discern long-term drug-
free remission. Only corticosteroid use at study entry 
was associated with shorter time to flare after treatment 
withdrawal, which may reflect greater disease severity in 
patients using corticosteroids or the difficulties associated 
with corticosteroid withdrawal.6 Notably, in ADJUST, a 
phase II double-blind treatment withdrawal trial, patients 
with undifferentiated or very early RA and ACPA posi-
tivity were treated with intravenous abatacept or placebo 
for 6 months, followed by treatment discontinuation. 
Patients receiving abatacept showed delayed disease 
progression and prolonged inhibition of radiographic 
progression after cessation of treatment versus placebo, 
and a decrease from baseline in rheumatoid factor and 
ACPA titres (however, the titres failed to reach the limits 
of normal).9
Most patients experiencing a flare entered the re-treat-
ment period, during which treatment with abatacept 
plus methotrexate notably reduced disease activity and 
improved physical function. LDA was recaptured in three 
quarters of patients, with two-thirds regaining remis-
sion. This is notable given the relatively high disease 
activity, as captured by the mean DAS28-CRP values, of 
study patients at the time of flare. Only PtGA predicted 
recapture of remission during re-treatment, suggesting 
that patients are the best judges of their own disease.
Very few SAEs were reported in the withdrawal or 
re-treatment periods. For the first time to our knowledge, 
lower infection rates were demonstrated in the with-
drawal and re-treatment periods versus the initial treat-
ment period. Infection rates in RA studies are usually 
regarded as an indicator of disease-modifying antirheu-
matic drug (DMARD)–associated toxicity. However, 
infection rates, including serious infections, probably 
reflect a complex interplay between the RA state, the 
disease-activity level and all therapies employed.10 11 
The observed infection rate in the withdrawal period 
(table 3) may simply reflect the absence of DMARD use. 
However, this does not explain the relatively similar rate 
of infection during re-treatment, notably in the group 
initially receiving methotrexate, without previous expo-
sure to abatacept. A linear relationship was demonstrated 
between serious infection rates and disease activity, with 
infection rates and disease activity tending to decrease 
over time on treatment.12 Further understanding of the 
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Table 4 Exposure-adjusted incidence rates of infection per 100 patient-years during the treatment, withdrawal and re-
treatment periods
Treatment months 0–6
(n=351)
Treatment months 
6–12
(n=351)
Withdrawal
(n=225)
Re-treatment
(n=146)
Overall rate – – 8.9* 16.1†
Abatacept+MTX 116.6 64.6 7.2 17.2
Abatacept 126.1 66.5 6.0 9.3
MTX 110.7 72.8 13.5 22.3
*All patients who entered the withdrawal period.
†All patients who experienced protocol-defined rheumatoid arthritis flare after treatment withdrawal, entered the re-treatment period and 
received open-label abatacept+MTX.
MTX, methotrexate.
factors influencing the development of infections and 
their interactions will assist in designing better, less toxic 
treatment strategies. The relative safety of withdrawal and 
re-treatment in this setting can, however, be stressed.
Limitations of this analysis include the high discon-
tinuation rate before the second 6 months of the with-
drawal period. At study conception, a formal definition 
of flare was unavailable; therefore, the designers formu-
lated their own robust definition. However, the Outcome 
Measures in Rheumatology Clinical Trials RA Flare Core 
Domain Set is now available13 and may have use in future 
clinical trials and practice by testing domains using the 
RA-flare questionnaire.14
This analysis demonstrates that, after receiving only 12 
months of DMARD therapy before withdrawal of all RA 
treatments, few patients with severe early RA can maintain 
drug-free remission over 12 months. However, for those 
experiencing disease flare after treatment withdrawal, 
this unique investigation showed that re-treatment with 
abatacept plus methotrexate can restore remission or 
LDA in many patients, with good tolerability.
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